Concert Pharmaceuticals is a clinical stage biopharmaceutical company applying its knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. The Company's approach typically starts with approved drugs that may be improved with deuterium substitution. Concert Pharmaceuticals's technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. The Company's deuterated chemical entity platform, or DCE Platform, has broad potential across numerous therapeutic areas.

Type
Public
HQ
Lexington, US
Founded
2006
Size (employees)
69 (est)
Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, US
Report incorrect company information

Key People/Management at Concert Pharmaceuticals

Roger Tung

Roger Tung

Founder, President, CEO & Board of Directors
Nancy Stuart

Nancy Stuart

COO
Lynette Herscha

Lynette Herscha

General Counsel
James Cassella

James Cassella

Chief Development Officer

Concert Pharmaceuticals Office Locations

Concert Pharmaceuticals has an office in Lexington
Lexington, US (HQ)
500 99 Hayden Ave
Show all (1)
Report incorrect company information

Concert Pharmaceuticals Financials and Metrics

Concert Pharmaceuticals Financials

Concert Pharmaceuticals's revenue was reported to be $143.89 m in FY, 2017
USD

Net income (Q1, 2018)

(4.5 m)

EBIT (Q1, 2018)

(3.8 m)

Market capitalization (14-Jun-2018)

458.3 m

Closing share price (14-Jun-2018)

19.6

Cash (31-Mar-2018)

35.7 m
Concert Pharmaceuticals's current market capitalization is $458.3 m.
Annual
USDFY, 2017

Revenue

143.9 m

General and administrative expense

21 m

R&D expense

30.2 m

Operating expense total

51.2 m
Quarterly
USDQ1, 2018

General and administrative expense

5.6 m

R&D expense

8.7 m

Operating expense total

14.3 m

EBIT

(3.8 m)
Annual
USDFY, 2017

Cash

27.7 m

Accounts Receivable

155 k

Current Assets

205.7 m

PP&E

2.2 m
Quarterly
USDQ1, 2018

Cash

35.7 m

Accounts Receivable

128 k

Current Assets

219.5 m

PP&E

4.4 m
Annual
USDFY, 2017

Net Income

95.6 m

Depreciation and Amortization

1 m

Accounts Payable

113 k

Cash From Operating Activities

102.9 m
Quarterly
USDQ1, 2018

Net Income

(4.5 m)

Depreciation and Amortization

253 k

Accounts Payable

236 k

Cash From Operating Activities

(12.5 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Concert Pharmaceuticals News and Updates

Report incorrect company information